Mineralys Therapeutics’ (MLYS) “Outperform” Rating Reaffirmed at Lifesci Capital

Mineralys Therapeutics (NASDAQ:MLYS)‘s stock had its “outperform” rating reissued by research analysts at Lifesci Capital in a research note issued on Tuesday, Zacks.com reports. Lifesci Capital also issued estimates for Mineralys Therapeutics’ FY2024 earnings at ($2.04) EPS.

Mineralys Therapeutics Stock Performance

MLYS stock opened at $12.78 on Tuesday. The firm has a fifty day moving average price of $13.17 and a 200 day moving average price of $10.10. Mineralys Therapeutics has a fifty-two week low of $5.85 and a fifty-two week high of $17.70. The firm has a market cap of $634.27 million and a PE ratio of -6.39.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its earnings results on Thursday, March 21st. The company reported ($0.61) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.24. On average, equities analysts predict that Mineralys Therapeutics will post -2.64 EPS for the current year.

Insider Buying and Selling at Mineralys Therapeutics

In other news, major shareholder Samsara Biocapital Gp, Llc purchased 555,555 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were acquired at an average price of $13.50 per share, with a total value of $7,499,992.50. Following the transaction, the insider now owns 5,074,916 shares of the company’s stock, valued at $68,511,366. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Institutional Investors Weigh In On Mineralys Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Catalys Pacific LLC bought a new stake in Mineralys Therapeutics during the fourth quarter valued at about $79,073,000. Samsara BioCapital LLC purchased a new position in shares of Mineralys Therapeutics in the 1st quarter valued at approximately $70,773,000. Braidwell LP boosted its stake in Mineralys Therapeutics by 267.8% in the 3rd quarter. Braidwell LP now owns 2,023,900 shares of the company’s stock worth $19,247,000 after purchasing an additional 1,473,600 shares in the last quarter. FMR LLC grew its position in Mineralys Therapeutics by 62.6% during the 3rd quarter. FMR LLC now owns 1,188,653 shares of the company’s stock worth $11,304,000 after purchasing an additional 457,815 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Mineralys Therapeutics by 4.3% during the 4th quarter. Vanguard Group Inc. now owns 977,980 shares of the company’s stock valued at $8,411,000 after purchasing an additional 40,342 shares in the last quarter. Institutional investors own 84.46% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension.